Acute Myelogenous Leukemia. Totowa, NJ: Humana Press; 2007: 177–92.. Impact of cytogenetics on clinical outcome in AML. In (ed.),
2009). , , (eds.), http://cgap.nci.nih.gov/Chromosomes/Mitelman (
Transcription factors in myeloid development: balancing differentiation with transformation. Nat Rev Immunol 2007;7:105–17., .
Acute promyelocytic leukemia: A paradigm for differentiation therapy. Cancer Treat Res, 2009;145: 219–35, , , .
High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008;111:4329–37., , et al.
Role of nuclear receptor corepressors in leukemogenesis. Curr Top Microbiol Immunol 2001;254:165–85., .
Epigenetics in acute myeloid leukemia. Semin Oncol 2008;35:378–87., , ,
Chromosomal rearrangements leading to MLL gene fusions: clinical and biological aspects. Cancer Res 2008;68:10024–7., .
dysregulation in myeloid leukemogenesis. Ann N Y Acad Sci 2007;1106:114–42., , et al. NUP98
The partial tandem duplication of ALL1 in acute myeloid leukemia with normal cytogenetics or trisomy 11 is restricted to one chromosome. Proc Natl Acad Sci USA 1997;94:3899–902., , et al.
Chromosome 5q deletion and epigenetic suppression of the gene encoding alpha-catenin (CTNNA1) in myeloid cell transformation. Nat Med 2007;13:78–83., , et al.
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature 2008;451:335–9., , et al.
Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 2009;23:1252–6..
Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?Blood 2007;109:431–48., , , , .
Deregulation of signaling pathways in acute myeloid leukemia. Semin Oncol 2008;35:336–45., , .
FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007;110:1262–70., , et al.
Prognostic relevance of FLT3-TKD mutations in AML: the combination matters – an analysis of 3082 patients. Blood 2008;111:2527–37., , et al.
FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008;111:1552–9., , et al.
Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 2001;61:7233–9., , et al.
Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002;99:4326–35., , et al.
The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008;111:2776–84., , et al.
Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 2005;65:9152–4., , et al.
Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. New Engl J Med 2005;352:254–66., , et al.
Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007;109:874–85., , , .
AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biological, pathological, immunophenotypic, and prognostic features. Blood 2009;114:3024–32., , et al.
Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 2008;26:5088–93., , et al.
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood 2009;113:2795–804., , et al.
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. New Engl J Med 2008;358:1909–18., , et al.
Prognostic significance of, and gene and microRNA expression signatures associated with, CEBPA mutations in cytogenetically normal acute myeloid leukemia with high-risk molecular features: a Cancer and Leukemia Group B Study. J Clin Oncol 2008;26:5078–87., , et al.
Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009;113:3088–91., , et al.
Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia. Impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010;28:2739–47., , et al.
Independent prognostic factors for AML outcome. Hematology Am Soc Hematol Educ Program 2009; 385–95., .
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009;114:144–7., , et al.
Mutation in TET2 in myeloid cancers. New Engl J Med 2009;360:2289–301., , et al.
Advances in molecular genetics and treatment of core-binding factor acute myeloid leukemia. Curr Opin Oncol 2008;20:711–18., , , .
World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008., , et al. (eds.).
Familial myelodysplasia and acute myeloid leukaemia – a review. Br J Haematol 2008;140:123–32., , .
Inherited aplastic anaemias/bone marrow failure syndromes. Blood Rev 2008;22:141–53., .
The genetic and molecular basis of Fanconi anemia. Mutat Res 2009;668:11–19., .
Acute myeloid leukaemia. Lancet 2006;368:1894–907., .
Therapy-related myeloid leukemia. Semin Oncol 2008;35:418–29., .
Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:620–5., , et al.
World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001., , , (eds.).
Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006;135:450–74., , et al.
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009;113:1875–91., , et al.
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453–74., , et al.
Development of minimal residual disease directed therapy in acute myeloid leukemia. Semin Oncol 2008;35:388–400., , .
Diagnosis of Fanconi anemia in patients with bone marrow failure. Haematologica 2009;94:487–95., , et al.
Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Leukemia 1999;13:1901–28., , et al.
Recurrent finding of the FIP1L1-PDGFRA fusion gene in eosinophilia-associated acute myeloid leukemia and lymphoblastic T-cell lymphoma. Leukemia 2007;21:1183–8., , et al.
Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia. J Mol Diagn 2010;12:3–16., , .
Minimal residual disease levels assessed by NPM1 mutation specific RQ-PCR provide important prognostic information in AML. Blood 2009;114:2220–31., , et al.
Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica 2009;94:54–60., , et al.
High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin Cancer Res 2005;11:6520–7., , et al.
The leukemic stem cell niche – current concepts and therapeutic opportunities. Blood 2009;114:1150–7., , .
A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood 2009;113:291–8., , .
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003;21:4642–9., , et al.
Standardization and quality control studies of ‘real-time’ quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia – a Europe Against Cancer program. Leukemia 2003;17:2318–57., , et al.
Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) – a Europe Against Cancer program. Leukemia 2003;17:2474–86., , et al.
Real-time quantitative PCR detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: A European LeukemiaNet study. J Clin Oncol 2009;27:5195–201., , et al.
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008;26:4944–51., , et al.
Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009;27:3650–8., , et al.
Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005;129:18–34., , , .
Minimal residual disease diagnostics in myeloid malignancies in the post transplant period. Bone Marrow Transplant 2008;42:145–57., , et al.
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010;116:354–65., , et al.
Minimal residual dieases-directed theropy for childhood acute myeloid leukemia: results of the AML02 multicentre trial. Lancet Oncol 2010;11:543–52., , et al.
2010 Jul 12 [Epub ahead of print]., , et al. Prognostic impact of minimal residual dieases in CBFB-MYH11-positive acute myeloid leukemia. J Clin Oncol